Pharmakologische Beeinflussung der Freisetzung von t-PA aus dem Gefäßendothel

H.-P. Kiöcking

doi:10.1055/s-0038-1660284

Hämostaseologie, Table of Contents

Hamostaseologie 1991; 11(02): 76-88
DOI: 10.1055/s-0038-1660284

Originalarbeiten

Schattauer GmbH

Pharmakologische Beeinflussung der Freisetzung von t-PA aus dem Gefäßendothel

H.-P. Kiöcking

¹Institut für Pharmakologie und Toxikologie der Medizinischen Akademie Erfurt

› Author Affiliations

Abstract

Zusammenfassung

Die akute Freisetzung von tissue-type Plasminogenaktivator (t-PA) aus dem Gefäßendothel hat eine entscheidende Bedeutung für die Verhütung intravasaler Fibrinablagerungen.

Mediatoren (plättchenaktivierender Faktor, Bradykinin, Histamin), adrenerge und cholinerge Transmitter (Isoprenalin, Acetylcholin), Gerinnungsfaktoren (Thrombin, Faktor Xa), polyanionische Verbindungen (Heparin, Pentosanpolysulfat, Natriumhumat, Enoxaparin-Natrium, Defibrotide), aliphatische Alkohole (Methanol, Ethanol, Propanol, Butanol) und 1-Desamino-8-D-argininvasopressin (DDAVP) bewirken am isoliert durchströmten Gefäßpräparat (Schweineohr) eine dosisabhängige t-PA-Freisetzung. Auch im Tierexperiment (Ratte, Kaninchen, Minischwein) kann eine Erhöhung der t-PA-Aktivität mit den meisten Verbindungen erreicht werden. Die t-PA-freisetzende Wirkung von DDAVP hat für diagnostische Zwecke Eingang in die Praxis gefunden. Eine pharmakologische Stimulierung der t-PA-Freisetzung könnte zur kurzzeitigen Thromboseprophylaxe und zur partiellen Thrombolyse genutzt werden. Dazu wären gegenwärtig nur Antithrombotika in der Lage, deren t-PA-Freisetzung erwiesen ist.

Full Text

References

LITERATUR
1 Aberg M, Nilsson IM, Vilhardt H. The release of fibrinolytic activator and factor VIII after injection of DDAVP. In: Davidson JF, Cepelak V, Samama MM, Desnoyers PC. (eds). Progress in Chemical Fibrinolysis and Thrombolysis. Vol. 4. Edinburgh, London, New York: Churchill Livingstone; 1979: 92-7.
2 Agnelli G, Borm J, Cosmu B, Levi M, ten Cate JW. Effect of standard heparin and a low molecular weight heparin (Kabi 2165) on fibrinolysis. Thromb Haemost 1988; 60: 311-3.
3 Ambrus JL, Ambrus CM, Jacobsen R, Schor JM, Jainchill JL. Clinical pharmacology study of an isoquinoline derivative (EN 1661) and of its ability to induce fibrinolytic activity in the circulation of man. Curr Ther Res 1970; 12: 451-6.
4 Andrade-Gordon P, Strickland S. Interaction of heparin with plasminogen activators and plasminogen: Effects on the activation of plasminogen. Biochemistry 1986; 25: 4033-6.
5 Arnesen H, Engebretsen LF, Ugland OM, Seljeflot I, Kierulf P. Increased fibrinolytic activity after surgery induced by low dose heparin. Thromb Res 1987; 45: 553-9.
6 Astrup T, Buluk K. Thromboplastic and fibrinolytic activities in vessels of animals. Circul Res 1963; 13: 253-6.
7 Bachmann F. Fibrinolysis. In: Verstraete M, Vermylen J, Lijnen R, Arnout J. (eds). Thrombosis and Haemostasis. Leuven: University Press; 1987: 227-65.
8 Barbanti M, Mastacchi R. The effect of heparin and OP/LMWH on the release of plasminogen activator in perfused rat hind legs. Thromb Haemost 1987; 58: 554 (Abstr).
9 Bevilacqua MP, Schleef RR, Gimbrone MA, Loskutoff DJ. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin-1. J Clin Invest 1986; 78: 587-91.
10 Binder BR. Gefäßwand und Fibrinolyse. Physiologische Aspekte. Folia Haematol 1986; 113: 151-63.
11 Booth F, Allington MJ, Cederholm-Williams SA. An in vitro model for the study of acute release of von Willebrand factor from human endothelial cells. Br J Haematol 1987; 67: 71-8.
12 Booth F, Marshall IM, Cederholm-Williams SA. Effect of bradykinin on the exposure of tissue plasminogen activator from human endothelial cells. Fibrinolysis 1988; 02: 107-10.
13 Booyse FM, Bruce R, Dolenak D, Grover M, Casey LC. Rapid release and deactivation of plasminogen activators in human endothelial cell cultures in the presence of thrombin and ionophore A 23187. Semin Thromb Hemost 1986; 12: 228-30.
14 Booyse FM, Bruce R, Gianturco SH, Bradley WA. Normal but not hypertriglyceridemic very low-density lipoprotein induces rapid release of tissue plasminogen activator from cultured human umbilical vein endothelial cells. Semin Thromb Hemost 1988; 14: 175-9.
15 Boulton FE, Prowse CV, Cash JD. On the mechanism of plasminogen activator release by DDAVP: animal studies. Thromb Haemost 1981; 46: 212 (Abstr).
16 Bounameaux H, Lijnen HR, Hellemans H, Verstraete M. Effect of standard and low molecular weight heparin fractions on fibrinolysis and platelet aggregation in patients undergoing hysterectomy. Thromb Haemost 1986; 55: 298.
17 Brommer EJP. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis, inefficiency of activators added afterwards. Thromb Res 1984; 34: 109-15.
18 Brommer EJP, Barrett-Bergshoeff MM, Allen RA, Schicht J, Bertina RU, Schalekamp MDA. The use of desmopressin acetate (DDAVP) as a test of the fibrinolytic capacity of patients analysis of responders and non-responders. Thromb Haemost 1982; 48: 156-61.
19 Buluk K, Zuch A, Januszko T. The production of plasminogen activator during perfusion of isolated rabbit kidneys. Experientia 1973; 29: 90-1.
20 Campani M. Farmaci attivatori della fibrinolisi. Minerva Chir 1963; 18: 1118-27.
21 Cash JD, Gader AMA, Mulder JL, Cort JH. Structure-activity relations of the fibrinolytic response to vasopressins in man. Clin Sci Mol Med 1978; 54: 403-9.
22 Cash TK, Chan V. The effect of venous occlusion on antithrombin III, plasminogen activator and fibrinogen degradation product (fragment E) levels. Thromb Res 1979; 14: 525-34.
23 Cavanagh RL, Imanishi H, Bibbeus JD, Taylor CH, Moylan DS, Buyniski JP. Possible mechanism for the fibrinolytic effect of certain bis-tetrahydroisoquinolines: evidence for histamine release. Thromb Res 1974; 05: 633-45.
24 Cercek B, Lew AS, Hod H, Yano J, Reddy NKN, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986; 74: 583-7.
25 Cercek B, Lew AS, Satoh Y, Isojima K, Laramee P, Yano J, Reddy KNN, Maddahi J, Ganz W. Heparin enhances experimental thrombolysis by preventing new fibrin deposition. Circulation 1985; 72 (Suppl III): 194.
26 Cho MH, Choy W. Induction of increased fibrinolytic activator in plasma by various drugs. Thromb Diath Haemorrh 1964; 11: 372-92.
27 Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89.
28 Cort JH, Dodds J, Nemerson Y, Marx G. Vasopressin as releasor of a factor VIII and plasminogen activator releasing factors from the brain. In: Sutor AH. (Hrsg). Minirin: DDAVP-Anwendung bei Blutern. Stuttgart, New York: Schattauer; 1980: 30-2.
29 Doutremepuich C, Toulemonde F, Doutremepuich F, De Seze O, Bayrou B, Pereira F. The t-PA-like activity induced by heparin and a heparin fragment binds on experimental thrombus. Thromb Res 1988; 50: 335-8.
30 Emeis JJ. Mechanisms involved in shortterm changes in blood levels of t-PA. In: Kluft C. (ed). Tissue-type plasminogen activator (t-PA): physiological and clinical aspects. Vol. II. Boca Raton: CRC Press; 1988: 21-35.
31 Emeis JJ. Perfused rat hindlegs. A model to study plasminogen activator release. Thromb Res 1983; 30: 195-203.
32 Emeis JJ, Kooistra T. Interleukin-1 and lipopolysacharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-6.
33 Emeis JJ, Kluft C. PAF-acether-induced release of tissue-type plasminogen activator from vessel walls. Blood 1985; 66: 86.
34 Erikson E, Wollter IM, Christenson B, Stigendal L, Risberg B. Heparin and fibrinolysis-comparison of subcutaneous administration of unfractionated and low molecular weight heparin. Thromb Haemost 1988; 59: 284-8.
35 Eyüboglu H, Akcasu A. The effects of compound 48/80 on the fibrinolytic activity of dogs. Thromb Haemost 1979; 41: 384-91.
36 Fareed J, Walenga JM, Hoppensteadt DA, Messmore HL. Studies on the profibrinolytic actions of heparin and its fractions. Semin Thromb Hemost 1985; 11: 199-207.
37 Fox KAA, Robison AK, Knabb RM, Rosamond TL, Sobel BE, Bergmann SR. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 1985; 72: 1346-54.
38 Gader AMA, Clarkson AR, Cash JD. The plasminogen activator and coagulation factor VIII responses to adrenaline, noradrenaline, isoprenaline and salbutamol in man. Thromb Res 1973; 02: 9-16.
39 Gader AMA, da Costa J, Parker SM, Cash JD. The systemic release of plasminogen activator to intravenous adrenaline in man: dose response studies. Thromb Res 1973; 03: 51-7.
40 Gader AMA, da Costa J, Cash JD. A new vasopressin analogue and fibrinolysis. Lancet 1973; 02: 1417-8.
41 Gader AMA, da Costa J, Cash JD. 1-Desamino-8-D-arginine vasopressin and fibrinolysis in man. Scott Med J 1974; 19: 56-7.
42 Gader AMA, Parker S, Crompton GK, Cash JD. Fibrinolytic, factor VIII and pulse rate responses to intravenous adrenaline during chronic oral salbutamol administration. Thromb Res 1973; 03: 137-43.
43 Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activatorinhibitor in cultured human endothelial cells. J Clin Invest 1986; 77: 165-9.
44 Gerald DEF, Szeto ILF, Spero J, Lewis JH. The thrombolytic effect of heparin and a heparin-like substance, SP₅₄ . Thromb Diath Haemorrh 1967; 17: 418-22.
45 Hagiwara H, Shimonaka M, Morisaki M, Ikekawa N, Inada Y. Sitosterol-stimulative production of plasminogen activator in cultured endothelial cells from bovine carotid artery. Thromb Res 1984; 33: 363-70.
46 Halse T. Heparin and Heparinoide. Dicumarol. Zürich: S. Hirzel; 1950
47 Halse T. Aktivierung der Fibrinolyse und Thrombolyse durch Polysaccharidschwefelsäureester (Heparin, Heparinoide). Arzneimittelforschung 1962; 12: 574-82.
48 Halse T. Poly electrolytes as activators of fibrinolysis and thrombolysis. Sangre 1964; 09: 149-52.
49 Hanss M, Collen D. Secretion of tissuetype plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin and histamine. J Lab Clin Med 1987; 109: 97-104.
50 Hart DA, Rehemtulla A. Plasminogen activators and their inhibitors : Regulators of extracellular proteolysis and cell function. Comp Biochem Physiol 1988; 90B: 691-708.
51 Helbig B, Klöcking R. Darstellung und Charakterisierung von Huminsäure-Modellsubstanzen. Z Physiother 1983; 33: 31-7.
52 Hijikata A, Hirata A, Kitaguchi H. Effect of protease on plasminogen activator release from isolated perfused dog leg. Thromb Res 1980; 20: 521-31.
53 van Hinsbergh VWM. Regulation of the synthesis and secretion of plasminogen activators by endothelial cells. Haemostasis 1988; 18: 307-27.
54 van Hinsbergk VWM, Kooistra T, van den Berg EA, Princen HMG, Fiers W, Emiess JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72: 1467-73.
55 Hofmann B, Meisgeier U, Ostermann G, Klöcking HP, Hoffmann A, Till U. Effect of BN 52021 on PAF-induced release of tissue-type plasminogen activator. In: Braquet P. (ed). Ginkgolides-Chemistry. Biology, Pharmacology and Clinical Perspectives. Vol. 2. Barcelona: Prous Science Publishers; 1989: 291-303.
56 Holemans R. Die Verstärkung der fibrinolytischen Aktivität des Blutes durch gefäßwirksame Pharmaka. Med Exp 1963; 09: 5-12.
57 Holemans R, Langdell RD. Histamineinduced increase in fibrinolytic activity. Proc Soc Exp Biol Med 1964; 115: 584-7.
58 Holemans R, Johnston JG, Reddick RL. Release of plasminogen activator by the isolated perfused dog kidney. Nature 1965; 208: 91.
59 Holemans R, Adamis D, Horace JF. Interaction of heparin with fibrinolysis. Thromb Diath Haemorrh 1963; 09: 447-58.
60 Holemans R, Adamis D, Horache JF. Heparine at fibrinolysis. Experientia 1962; 18: 377-8.
61 Holemans R, Mann LS, Mlynarczyk EJ, Poiesz BJ. Drug-induced plasminogen activator release. Thromb Diath Haemorrh 1967; 18: 298-304.
62 Hussaina I, Moore PK. Fibrinolytic effect of prostanoids in the rat. Br J Pharmacol 1985; 86: 813.
63 Ichinose A, Fujikawa K, Suyama T. The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-9.
64 Inada Y, Hagiwara H, Kojima S, Shimonaka M, Saito Y. Synergism of vitamins A and C on fibrinolysis. Biochem Biophys Res Commun 1985; 130: 182-7.
65 Isacson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent »diopathie« venous thrombosis. Acta Chir Scand 1972; 138: 313-9.
66 Izaki S, Kitaguchi H. Calcium dependent and independent release of plasminogen activator from the vascular wall. Thromb Res 1977; 10: 765-70.
67 Jablonowski C, Klöcking HP, Markwardt F. Experimentelle Untersuchungen zur Freisetzung von Plasminogenaktivator durch DDAVP. Folia Haematol 1984; 111: 567-74.
68 Johansson L, Hedner U, Nilsson IM. A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall. Acta Med Scand 1978; 203: 477-80.
69 von Kaulla KN, McDonald TS. The effect of heparin on components of the human fibrinolytic system. Blood 1958; 13: 811-21.
70 Kertscher HP, Ostermann G, Lang A, Weissflog W, Gawrick K. Synthese und biologische Aktivität einiger stabiler Strukturanaloga des plättchenaktivierenden Faktors. Pharmazie 1985; 40: 702-4.
71 Kirchheimer JC, Pflüger H, Hienert G, Binder BR. Increased urokinase activity to antigen ratio in human renal cell carcinoma. Int J Cancer 1985; 35: 737-41.
72 Kitaguchi H, Hijikata A, Hirata M. Effect of thrombin on plasminogen activator release from isolated perfused dog leg. Thromb Res 1979; 16: 407-20.
73 Kitaguchi H, Izaki S. A physiological study on the releasing mechanism of plasminogen activator from the vascular wall. Thromb Diath Haemorrh 1975; 34: 351-6.
74 Klauser RJ, Meinetsberger E, Raake W, Zeiller P. New synthetic heparinoids: chemistry, anticoagulatory and antithrombotic properties of bis-lactobionic acid amides. Thromb Haemorrh Disorders 1990; 02: 75-81.
75 Kleniewski J, Jaworska-Bzymek D. The influence of insulin and glucose on the release of plasminogen activator by isolated rabbit kidneys. Experientia 1974; 30: 1032-3.
76 Klöcking HP. Pharmacological stimulation of t-PA release in rats. Fibrinolysis 1990; 04 (Suppl. 02) 45-6.
77 Klöcking HP. Stimulation of t-PA release by poly anionic compounds in vivo. Thromb Res. (in press).
78 Klöcking HP. Zum Mechanismus von Plasminogenaktivatoren. In: Tilsner V, Matthias FR. (Hrsg). Blutgerinnung und Onkologie. Basel, Grenzach-Wyhlen: Editiones »Roche«; 1989: 167-70.
79 Klöcking HP. Influence of defibrotide on acute t-PA releasing effect in vivo and in vitro. Thromb Res. (in press).
80 Klöcking HP. Release of plasminogen activator by acetylcholine from the isolated perfused pig ear. Thromb Res 1979; 16: 261-4.
81 Klöcking HP, Astedt B, Gerlach D. Characterization of the vascular plasminogen activator from the pig ear. Folia Haematol 1984; 111: 851-61.
82 Klöcking HP, Bock G, Drawert J, Hinsenbrock KP, Kaiser B, Sedlarik K. Über die Freisetzung von Plasminogenaktivatoren. Folia Haematol 1976; 103: 404-24.
83 Klöcking HP, Hoffmann A. Regulation of t-PA release in the isolated perfused pig ear by protein kinase C and cAMP. In: Sinzinger H, Vinazzer H. (eds). Thrombosis and Haemorrhagic Disorders. Würzburg: Schmitt & Meyer; 1989: 452-4.
84 Klöcking HP, Markwardt F, Güttner J. On the mechanism of batroxobin-induced fibrinolysis. Pharmazie 1989; 44: 504-5.
85 Klöcking HP, Hoffmann A, Markwardt F. Release of plasminogen activator by pentoxifylline and its major metabolite. Thromb Res 1987; 46: 747-50.
86 Klöcking HP, Hoffmann A, Markwardt F. Release of plasminogen activator by SIN-1. Pharmazie 1987; 42: 354.
87 Klöcking HP, Hoffmann A, Markwardt F. Release of plasminogen activator by SIN-1. Pathol Biol 1987; 35: 231-2.
88 Klöcking HP, Hoffmann A, Markwardt F. Influence of hirudin on the thrombininduced release of tissue plasminogen activator from isolated perfused pig ear. Folia Haematol 1988; 115: 110-2.
89 Klöcking HP, Hoffmann A, Markwardt F. Influence of α-NAPAP on the thrombin induced plasminogen activator release. Thromb Res 1988; 52: 71-3.
90 Klöcking HP, Hoffmann A, Ostermann G, Klöcking R, Eichhorn U, Kertscher HP. Studies on the biological activity of stable analogues of platelet activating factor. In: Ulutin ON, Vinazzer H. (eds). Thrombosis and Hemorrhagic Diseases. Istanbul: Gözlem; 1986: 459-61.
91 Klöcking HP, Hoffmann A, Ostermann G, Kertscher HP. Release of plasminogen activator and stimulation of platelets by stable analogues of platelet activating factor (PAF). Fibrinolysis 1987; 01: 129-31.
92 Klöcking HP, Hoffmann A, Markwardt F. Release of plasminogen activator by batroxobin. Haemostasis 1987; 17: 235-7.
93 Klöcking HP, Hoffmann A, Fareed J. Influence of hypersulfated lactobionic acids on acute t-PA releasing effect in the isolated perfused pig ear. Thromb Res. (in press).
94 Klöcking HP, Hoffmann A. Acute t-PA release by enoxaparin in vitro and in vivo. Thromb Res. (in press).
95 Klöcking HP, Helbig B, Drabke P. Eine verbesserte Methode für die Isolierung wasserlöslicher Huminsäuren und enzymatisch oxydierter o-Diphenolverbindungen. Pharmazie 1977; 32: 297.
96 Klöcking HP, Jablonowski C. Studies on the release of plasminogen activator. In: Davidson JF, Nilsson IM, Astedt B. (eds). Progress in Chemical Fibrinolysis and Thrombolysis. Vol. V. Edinburgh, London, New York: Churchill Livingstone: 1981: 353-6.
97 Klöcking HP, Jablonowski C, Markwardt F. Studies on the release of plasminogen activator from isolated rat lung by serine proteinases. Thromb Res 1981; 23: 375-9.
98 Klöcking HP, Klöcking R, Helbig B. Einfluß von Phenol-Körperpolymerisaten auf die Freisetzung von Plasminogen-Aktivatoren. Farmakol Toksikol 1984; 47: 93-6.
99 Klöcking HP, Markwardt F, Hoffmann A. Release of plasminogen activator by platelet-activating factor. Thromb Res 1985; 38: 413-6.
100 Klöcking HP, Markwardt F. Influence of mediators on the plasminogen activator release in an isolated organ preparation. In: Davidson JF. (ed). Progress in Chemical Fibrinolysis and Thrombolysis. Vol. IV. New York: Churchill Livingstone; 1979: 75-9.
101 Klöcking HP, Markwardt F. Pentosan polysulphate induced release of plasminogen activator. In: Davidson JF, Donati MB, Coccheri S. (eds). Progress in Fibrinolysis. Vol. VII. Edinburgh, London, Melbourne, New York: Churchill Livingstone; 1985: 313-5.
102 Klöcking HP, Markwardt F. Release of plasminogen activator by pentosan polyphosphate. Thromb Res 1986; 41: 739-44.
103 Klöcking HP, Nguyen TT, Sedlarik K. Zur Freisetzung von Plasminogenaktivator durch Pentosanpolysulfat. Folia Haematol 1986; 113: 236-54.
104 Klöcking HP, Sedlarik K. Influence of anaesthetics on the fibrinolytic activity in minipigs. Folia Haematol 1988; 115: 132-5.
105 Klöcking HP, Richter M, Markwardt F. On the thrombolytic effect of pentosan polysulphate in animals. Pharmazie 1988; 43: 440-1.
106 Klöcking HP, Ostermann G, Hoffmann A, Hofmann B, Kertscher HP. Inhibitory action of synthetic ether lipids and the ginkgolide BN 52021 on PAF-induced plasminogen activator release and platelet aggregation. Thromb Haemost Disorders 1990; 01: 7-10.
107 Koestering W, Koenig F, Weber S, Warmann S, Guerrero M. Einfluß von oral und transkutan appliziertem SP₅₄ auf präformierte Thromben im Tierversuch. Med Welt 1973; 24: 139-40.
108 Kojima S, Hagiwara H, Shimonaka M, Saito Y, Inada Y. Synergism of retonoids and L-ascorbic acid in producing plasminogen activator in endothelial cells. Biomed Res 1986; 07: 155-9.
109 Kooistra T, Bosma PJ, Jespersen J, Kluft C. Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables. Am J Obstet Gynecol. (in press).
110 Kooistra T, Hendriks HFJ, Emeis JJ. Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo. Fibrinolysis. (in press).
111 Korninger C, Niessner H, Thaler E, Lechner K. Wirkung von DDAVP auf Fibrinolyse und Gerinnungsparameter-Untersuchung an Normalpersonen, Hämophilen und Patienten mit von Willebrand-Jiirgens-Syndrom. In: Sutor AH. (Hrsg). Minirin: DDAVP-Anwendung bei Blutern. Stuttgart, New York: Schattauer; 1980: 55-64.
112 Kosman ME. Evaluation of a new antidiuretic agent, desmopressin acetate (DDAVP). J Am Med Assoc 1978; 240: 1896-7.
113 Kruithof EKO. Plasminogen activator inhibitors a review. Enzyme 1988; 40: 113-21.
114 Kuo BS, Korner G, Dryjski M, Bjornsson TD. Role of polyamines in the stimulation of synthesis and secretion of plasminogen activator from bovine aortic endothelial cells. J Cell Physiol 1988; 137: 192-8.
115 Lang WE. Ethyl alcohol enhances plasminogen activator secretion by endothelial cells. J Am Med Assoc 1983; 250: 772-6.
116 Levin EG, Marze U, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 1984; 74: 1988-95.
117 Levin EG, Loskutoff DJ. Comparative studies of the fibrinolytic activity of cultured vascular cells. Thromb Res 1979; 15: 869-78.
118 Lijnen HR, Collen D. Stimulation by heparin of the plasmin mediated conversion of single-chain to two-chain urokinasetype plasminogen activator. Thromb Res 1988; 43: 687-90.
119 Maffrand JP, Gachon M, Bayol A. Comparison of structures of pentosan polysulphate and other sulfated polysaccharides. 1st International Symposium on Pentosan Polysulphate, Paris. 8.6.1985 (Abstracts).
120 Mannucci PM. Enhancement of plasminogen activator by vasopressin and adrenaline: A role of cyclic AMP?. Thromb Res 1974; 04: 539-50.
121 Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93.
122 Manucci PM, Rota L. Plasminogen activator response after DDAVP: a clinicopharmacological study. Thromb Res 1980; 20: 69-76.
123 Markus G. The role of hemostasis and fibrinolysis in the metastatic spread of cancer. Semin Thromb Hemost 1984; 19: 61-70.
124 Markwardt F, Klöcking HP. Heparin-induced release of plasminogen activator. Haemostasis 1977; 06: 370-4.
125 Markwardt F, Klöcking HP. Studies on the release of plasminogen activator. Thromb Res 1976; 08: 217-23.
126 Markwardt F, Klöcking HP. Einfluß von Mediatoren auf die Freisetzung von Plasminogenaktivatoren. Acta Biol Med Ger 1978; 37: 1603-10.
127 Markwardt F, Klöcking HP, Hauptmann J, Faust G. On the fibrinolytic action of bis-6,7-dimethoxy-isoquinoline derivatives. Thromb Res 1973; 02: 383-92.
128 Marsh NA, Gaffney PJ. The effect of pentosan polysulphate (SP 54) on the fibrinolytic enzyme system. An experimental animal study. Folia Haematol 1986; 113: 255-61.
129 Marsh NA, Peyser PM, Creighton LJ, Mahmoud M, Gaffney PJ. The effect of pentosan polysulphate (SP 54) on the fibrinolytic enzyme system. A human volunteer and experimental animal study. Folia mental animal study. Thromb Haemost 1985; 54: 833-7.
130 Matsubara F, Sueishi K, Ishii Y, Tanaka K. Release of plasminogen activator from isolated perfused dog heart. Thromb Haemost 1985; 53: 126-9.
131 McArthur MM, MacGregor IR, Prowse CV, Hunter NR, Dawes I, Pepper DS. The use of human endothelial cells cultured in flat wells and on microcarrier beads to assess tissue plasminogen activator and factor VIII related antigen release. Thromb Res 1986; 41: 581-7.
132 Menanteau A, Bruno M, Quilichini R, Nougarede M. Utilisation de l’heparinoide hemoclar dans le traitement des insuffisances circulatoires arterielles en neurologie (a propos de 78 cas). Marseille Med 1965; 192: 11.
133 Nakajima K. Pharmacological observations of plasminogen activator release caused by vasoactive agents in isolated perfused pig ears. Thromb Res 1983; 29: 163-74.
134 Nakajima K. Effects of dilazep on fibrinolytic system in animals. II. Enhancing effect of dilazep on plasminogen activator release in the isolated perfused pig ear. J Pharmacobio-Dynam 1982; 05: 363-9.
135 Nakajima K. A possible mechanism of vasoactive agents on plasminogen activator release in isolated perfused pig ears. Thromb Res 1983; 29: 187-96.
136 Neerstrand H, Ostergaard P, Bergquist D, Mätzsch T, Hedner U. t-PA inhibitor, t-PA: Ag, plasminogen and α₂-antiplasmin after low molecular weight heparin or standard heparin. Fibrinolysis 1987; 01: 39-43.
137 Neumann C, Sorg C. Regulation of plasminogen activator secretion, interferon induction in murine macrophages. Eur J Immunol 1983; 13: 143-7.
138 Nilsson IM, Holmberg L, Aberg M, Vilhardt H. The release of plasminogen activator and factor VIII after injection of DDAVP in healthy volunteers and in patients with von Willebrand’s disease. Scand J Haematol 1980; 24: 351-9.
139 Nolf P. De la nature de l’hypoleucocyfose propeptonique. Arch Int Physiol 1904; 01: 242-5.
140 Paques EP, Stöhr HA, Heimburger N. Study on the mechanism of action of heparin and related substances on the fibrinolytic system: Relationsship between plasminogen activators and heparin. Thromb Res 1986; 42: 797-807.
141 Prowse CV, Dow R, Sheward J, Boulton F. The plasminogen activator response to direct hypothalamic stimulation in normal and congenitaly vasopressin-deficient rats. Haemostasis 1982; 11: 36.
142 Prowse CV, Mac Gregor IR. Regulation of plasminogen activator level in blood. In: Kluft C. (ed). Tissue-type plasminogen activator (t-PA): physiological and clinical aspects. Vol. II. Boca Raton: CRC Press; 1988: 49-66.
143 Raake W, Klauser RJ, Elling H, Meinetsberger E. Anticoagulant and antithrombotic properties of synthetic sulfated bislactobionic acid amides. Thromb Res 1989; 56: 719-30.
144 Rahn B, Kaulla KN. Pharmakologische tierexperimentelle Fibrinolyse. Klin Wochenschr 1965; 43: 163-9.
145 Rahn B, Kaulla KN. Pharmacological induction of fibrinolytic activity in the dog. Proc Soc Exp Biol Med 1964; 115: 359-62.
146 Rosing DR, Redwood DR, Brakman P, Astrup T, Epstein SE. The fibrinolytic response of man to vasoactive drugs measured in arterial blood. Thromb Res 1978; 13: 419-28.
147 Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci (USA) 1985; 82: 1121-5.
148 Sandritter W, Bergerhof HD, Kroker R. Morphologische Untersuchungen zur Wirkung des Heparins auf experimentelle Abscheidungsthromben. Frankf Z Path 1954; 65: 342-9.
149 Sandritter W, Schlüter G, Koppel G. Thrombolyse im Tierexperiment. Untersuchungen mit einem Polysaccharidsulfoester und Streptokinase. Med Welt 1964; 51: 2732-9.
150 Sandritter W, Bergerhof HD. Morphologische Studien zur Fibrinolyse an experimentellen Gerinnungsthromben. Frankf Z Path 1954; 65: 127-30.
151 Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988; 263: 5797-803.
152 Schneider J. Stimulation of the plasma fibrinolytic activity in rats by the prostacyclin analogue CG 4203. Thromb Res 1987; 48: 233-44.
153 Schor JM, Steinberger V, Tutko E, Aboulafia S, Tachter JJ, Jacobsen R. Studies with the synthetic fibrinolytic compound EN 1661. In: Schor JM. (ed). Chemical control of Fibrinolysis-Thrombolysis. Theory and Clinical Applications. New York, London, Sydney, Toronto: Wiley: 1970: 113-52.
154 Schorer AE, Moldow CF, Rieck ME. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells. Br J Haematol 1987; 67: 193-7.
155 Shimonaka M, Hagiwara H, Koljima S, Inada Y. Successive study on the production of plasminogen activator in cultured endothelial cells by phytosterol. Thromb Res 1984; 36: 217-22.
156 Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985; 66: 835-9.
157 Sprengel ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
158 Stelzer R. Therapie der Zentralvenenthrombose mit SP 54. Monatsbl Augenheilkd 1966; 249: 519-23.
159 Suffredini AF, Harpel PC, Parillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-72.
160 Tranquille N, Emeis JJ. The effect of pentoxifylline (Trental) and two analogs, BL 194 and HWA 448, on the release of plasminogen activators and von Willebrand factor in rats. (in press).
161 Tranquille N, Emeis JJ. Release of tissuetype plasminogen activator is induced in rats by leukotriens C4 and D4, but not by prostaglandins El, E2 and 12. Br J Pharmacol 1988; 93: 156-64.
162 Vairel EG, Bouty-Boye H, Toulemonde F, Doutremepuich D, Marsh NA, Gaffney PJ. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-24.
163 Vief B, Jäger H, Hellstern P, Wenzel E. Zum Einfluß von DDAVP auf das Gerinnungsund Fibrinolysesystem sowie auf die primäre Hämostase. In: Sutor FR. (ed). Vasopressin Analogues and Haemostasis/ DDAVP, TGLVP. Stuttgart, New York: Schattauer; 1981: 57-64.
164 Vinazzer H. Untersuchungen über die fibrinolytische Wirkung des Heparins. Wien Z Inn Med 1951; 23: 167-73.
165 Vinazzer H. Klinische Untersuchungen zur fibrinolytischen Wirkung von Pentosanpolysulfat. Folia Haematol 1986; 113: 272-7.
166 Vinazzer H, Sternberger A, Haas S, Blümel G. Influence of heparin, of different heparin fractions and of a low molecular weight heparin-like substance on the mechanism of fibrinolysis. Thromb Res 1982; 27: 341-52.
167 Vogel G, Machulik M. Thrombolytic effects of a polyanionic compound (pentosanpoly sulphate SP 54) in geriatric patients. Thromb Haemost 1987; 58: 70 (Abstr).
168 Weiner M, de Crinis K, Redisch W, Steele JM. Influence of some vasoactive drugs on fibrinolytic activity. Circulation 1959; 19: 845-8.
169 Winther K, Snorrason K, Knudsen JB, Medgyesi S. The effect of prostacyclin infusion on tissue plasminogen activator. Thromb Res 1987; 46: 741-5.
170 Wun TC, Capuano A. Spontaneous fibrinolysis in whole human plasma. Identification of tissue activator-related protein as the major plasminogen activator causing spontaneous activity in vitro. J Biol Chem 1985; 260: 5061-6.
171 Zammaron C, Lijnen HR, Collen D. Influence of exogenous and endogenous tissuetype plasminogen activator on the lysability of clots in a plasma milieu in vitro. Thromb Res 1984; 35: 335-45.
172 Hoffmann A, Klöcking HP. Untersuchungen zur Freisetzung von Plasminogenaktivator durch SIN-1. Wiss Z Ernst-MoritzArndt-Univ Greifswald, Med Reihe 1988; 37: 132-4.
173 Kooistra T, Van den Berg AP, Emeis JJ, Princen JMG. Modulation of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PA-I) production by human endothelial cells (EC) and porcine hepatocytes (PH). Thromb Haemost 1985; 54: 171.